Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claire Doshier
Institution:
University of Arkansas for Medical Sciences
Observed institutions:
Vanderbilt University,
University of Arkansas for Medical Sciences
ORCID:
0009-0005-4302-068X
Observed ORCID:
0009-0005-4302-068X
OpenAlex ID:
A5043374875
Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2023
·
Mason McCrury
, Kennith Swafford
, et al.
·
Molecular Cancer Therapeutics
·
16
Damage-Induced Senescent Immune Cells Regulate Regeneration of the Zebrafish Retina
2024
·
James G. Patton
, Gregory J. Konar
, et al.
·
4
PDF
DNA secondary structures in BCL2 and MYC elicit activation-induced cytidine deaminase binding and activity
2026
·
Mason McCrury
, Ambrocio Sanchez
, et al.
·
Nucleic Acids Research
·
1
Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S1 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S1 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S2 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S11 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Figure S4 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Figure S5 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S8 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Supplemental methods from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Figure S1 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S3 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Table S3 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
PDF
Table S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Data from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
PDF
Table S10 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Supplemental methods from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
PDF
Table S5 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Supplementary Data - Tables from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024
·
Mason McCrury
, Kennith Swafford
, et al.
Show more works
View as search
Works count:
58
Citation count:
21
H-index:
2
I10-index:
1
Year
Topic
Type
